Compare EPR & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPR | RLAY |
|---|---|---|
| Founded | 1997 | 2015 |
| Country | United States | United States |
| Employees | 54 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.1B |
| IPO Year | N/A | 2020 |
| Metric | EPR | RLAY |
|---|---|---|
| Price | $62.07 | $19.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 10 |
| Target Price | ★ $58.94 | $19.50 |
| AVG Volume (30 Days) | 531.8K | ★ 4.2M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 6.28% | N/A |
| EPS Growth | N/A | ★ 31.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,355,000.00 |
| Revenue This Year | $2.66 | N/A |
| Revenue Next Year | $8.60 | $324.03 |
| P/E Ratio | $25.00 | ★ N/A |
| Revenue Growth | N/A | ★ 53.44 |
| 52 Week Low | $48.11 | $3.03 |
| 52 Week High | $62.18 | $20.79 |
| Indicator | EPR | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 68.87 | 62.76 |
| Support Level | $57.44 | $12.10 |
| Resistance Level | N/A | $20.79 |
| Average True Range (ATR) | 1.05 | 1.31 |
| MACD | 0.26 | -0.09 |
| Stochastic Oscillator | 79.41 | 73.40 |
EPR Properties is a real estate investment trust that focuses on underwriting experiential property investments on key industry and property cash flow criteria, and the credit metrics of tenants and customers. The company invests in two property segments: Experiential, including theaters, family entertainment centers, ski resorts, and other attractions; and Education, including early childhood education centers and private school properties. The company's business is focused on Experiential real estate. The majority of revenue comes from the Experiential sector.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.